北京大学肿瘤医院、北京肿瘤医院暨北京市肿瘤防治研究所 >> 教学工作
北京大学临床肿瘤学院教师简介
姓名 郭军 性别
民族 汉族 科室 肾癌黑色素瘤内科
职称 主任医师 教授 联系电话 010-88196317
专业 肿瘤学
E-MAIL guoj307@126.com
  研究方向(点击查看详细介绍)
肿瘤免疫治疗
肿瘤分子靶向治疗
  研究生招生计划
招生年度招生专业研究方向学位级别学位类型选拔方式备注
2020 肿瘤内科学 临床医疗技能训练与研究 博士 专业学位 申请考核制招生 申请考核制招生
  社会任职
国际黑色素瘤联盟(Society for Melanoma Research)亚太地区主席
中国临床肿瘤学会(CSCO)肾癌专业委员会主任委员
中国抗癌协会泌尿肿瘤分会常务委员
全球黑色素瘤专家委员会GMTF(Golbal Melanoma Task Force)常务委员
中国临床肿瘤学会(CSCO)黑色素瘤专业委员会主任委员
国际黑色素瘤基金会(MIF)海外咨询顾问
中国临床肿瘤协会(CSCO)执委会委员
中国抗癌协会肾癌专业委员会常务委员
中国晚期肾癌治疗专家委员会成员
中国临床肿瘤学会(CSCO) 副秘书长
《Journal of Cancer Research and Clinical Oncology》特约审稿专家
《中国肿瘤临床》特约审稿专家
《癌症》编委
《Clinical Cancer Research》特约审稿专家
《Melanoma Research》特约审稿专家
《NCCN肾癌诊治指南中国版》执笔人
《中华医学会«中国肾癌治疗指南》执笔人
《中国黑色素瘤诊治指南》编写组组长
国家教育部 “新世纪优秀人才支持计划”入选者
北京市“十百千”卫生优秀人才基金获得者
北京市卫生系统高层次技术人才(学科带头人)
北京市新世纪百千万人才工程
  学习、工作经历
2011.7 ~ 2019.4 , 北京肿瘤医院 肾癌黑色素瘤内科 副院长/科主任 主任医师/教授
2009.9 ~ 2011.6 , 北京肿瘤医院 肾癌黑色素瘤内科 党委副书记/科主任 主任医师/教授
2008.9 ~ 2009.8 , 北京肿瘤医院 肾癌黑色素瘤内科 党委副书记/科主任 主任医师/副教授
2006.1 ~ 2008.8 , 北京肿瘤医院 肾癌黑色素瘤内科 党委副书记/科主任 副主任医师/副教授
2003.9 ~ 2005.12 , 北京肿瘤医院 淋巴肿瘤内科 副主任医师/副教授
2002.8 ~ 2003.8 , 济南军区总医院 肿瘤内科 副主任医师/副教授
1999.9 ~ 2002.7 , 第二军医大学 免疫学研究所 免疫学 博士研究生
1995.8 ~ 1999.8 , 济南军区总医院 肿瘤内科 主治医师
1992.9 ~ 1995.7 , 第四军医大学 唐都医院 传染病 硕士研究生
1990.8 ~ 1992.8 , 济南军区总医院 心内科 住院医师
1984.9 ~ 1990.7 , 第四军医大学 军医系6年制 临床医学 本科
近5年发表学术论文(*为责任作者,#为共同第一作者)   >>更多
Ma M, Dai J, Tang H, Xu T, Yu S, Si L, Cui C, Sheng X, Chi Z, Mao L, Wu X, Yang L, Yu H, Li S, Lian B, Tang B, Wang X, Yan X, Bai X, Zhou L,Kong Y and Guo J. MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways. Theranostics,2019,9(4): 945-96
Sheng X, Cao D, Yuan J, Zhou F, Wei Q, Xie X, Cui C, Chi Z, Si L, Li S, Mao L, Lian B, Tang B, Yan X, Wang X, Kong Y, Dai J, Bai X, Zhou L, Guo J. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study European Journal of Cancer,2018,100:1-7
Xu T, Ma M, Chi Z, Si L, Sheng X, Cui C, Dai J, Yu S, Yan J, Yu H, Wu X, Tang H, Yu J, Kong Y, Guo J. High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis Cancer Science,2018,109(6):1787-1798
Yu J, Wu X, Yan J, Yu H, Xu L, Chi Z, Sheng X, Si L, Cui C, Dai J, Ma M, Xu T, Kong Y, Guo J. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. J Hematol Oncol.,2018,11(1):1
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors  BMC Cancer,2017,2017;17:16
Li S, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Tang B, Yan X, Wang X, Chi Z, Guo J. Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China Ann Surg Oncol.,2017
Ma M#, Dai J, Xu T, Yu S, Yu H, Tang H, Yan J, Wu X, Yu J, Chi Z, Si L, Cui C, Sheng X, Kong Y*,Guo J*. Analysis of TSC1 mutation spectrum in mucosal melanoma. Journal of Cancer Research and Clinical Oncology,2017
Yan Kong#, Xinan Sheng#, Xiaowen Wu#, Junya Yan, Meng Ma, Jiayi Yu, Lu Si,Zhihong Chi, Chuanliang Cui, Jie Dai, Yiqian Li, Huan Yu, Tianxiao Xu, Huan Tang,Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xieqiao Yan, Siming Li, and Jun Guo*. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma indicate the potential for CDK4/6 Inhibitors in Targeted Therapy. Clinical Cancer Research,2017,2017;23(22):6946-6957
Bai X#, Kong Y#, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J*, Si L*. MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical cancer research,2017,2017;23(20):6120-7
Wu X#, Yan J, Dai J, Ma M, Tang H, Yu J, Xu T, Yu H, Si L, Chi Z, Sheng X, Cui C, Kong Y*, Guo J*. Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma. Oncol Lett,2017,2017;14(3):3601-5
Yu J#, Wu X#, Yu H, Li S, Mao L, Chi Z, Si L, Sheng X, Cui C, Dai J, Ma M, Tang H, Xu T, Yan J, Kong Y*, Guo J*. Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon. Transl Oncol,2017,2017;10(5):719-25
Lian B, Cui CL, Zhou L, Song X, Zhang XS, Wu D, Si L, Chi ZH, Sheng XN, Mao LL, Wang X, Tang BX, Yan XQ, Kong Y, Dai J, Li SM, Bai X, Zheng N, Balch CM, Guo J*. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Ann Oncol,2017,2017;28(4):868-873
J. Guo, R. D. Carvajal, R. Dummer, A. Hauschild, A. Daud, B. C. Bastian, S. N. Markovic, P. Queirolo, A. Arance, C. Berking, V. Camargo, D. Herchenhorn, T. M. Petrella, D. Schadendorf, W. Sharfman, A. Testori, S. Novick, S. Hertle, C. Nourry, Q. Chen, F. S. Hodi. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial Annals of Oncology,2017,28: 1380–1387, 2017
Dai J, Wu S, Kong Y, Chi Z, Si L, Sheng X, Cui C, Fang J, Zhang J, Guo J*. Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma. Sci Rep,2017,2017;7:39597
Sheng X, Kong Y, Li Y, Zhang Q, Si L, Cui C, Chi Z, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Dai J, Guo J. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. Eur J Cancer,2016,2016;65:156-63
Sheng X, Kong Y, Li Y, Zhang Q, Si L, Cui C, Chi Z, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Dai J, Guo J*. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. Eur J Cancer,2016,2016;65:156-63
Agnieszka Malczewski, Andrea Marshal, Miranda J. Payne, Lili Mao, Dimitrios Bafaloukos, Lu Si, Dimitrios Pectasides, George Fountzilas, Jun Guo, Helen Gogas, Mark R. Middleton. Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials Cancer Medicine,2016,2016; 5(1):17–23
Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget,2016,2016;7(19):27044-54
Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget,2016,2016;7(19):27044-54
Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget,2016,2016;7(19):27044-54
Kong Y, Si L, Li Y, Wu X, Xu X, Dai J, Tang H, Ma M, Chi Z, Sheng X, Cui C, Guo J. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors. Clin Cancer Res,2016,2016;22(4):1018-27.
Sheng X, Li S, Chi Z, Si L, Cui C, Mao L, Lian B, Tang B, Wang X, Yan X, Kong Y, Dai J, Guo J*. Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients. Br J Ophthalmol,2015,2015;99(7):990-6
近3年承担的课程教学   >>更多
授课内容课时授课日期课程类别在线课件课程名称
肿瘤免疫治疗的临床生物学问题 3 2019/11/11 研究生课程 肿瘤生物学
肿瘤生物治疗总论 2 2019/10/21 研究生课程 肿瘤学总论
肿瘤临床研究中的研究者职责 1 2019/5/15 研究生课程 肿瘤临床研究的实践
肿瘤免疫治疗概论 2 2019/3/5 研究生课程 临床肿瘤免疫学
肿瘤免疫治疗的临床生物学问题 3 2018/11/14 研究生课程 肿瘤生物学
肿瘤生物治疗总论 2 2018/10/22 研究生课程 肿瘤学总论
CSCO 2018第四届北京黑色素瘤国际研讨会2018-03-10-036(国) 12 2018/8/25 三基培训
肿瘤临床研究中的研究者职责 1 2018/5/9 研究生课程 肿瘤临床研究的实践
肿瘤临床研究的设计与研究者职责 1 2017/5/3 研究生课程 肿瘤临床研究的实践
1